Minerva Neurosciences closed at $2.35 on Nov 3, up 0.21%, 70.9% below its 52-week closing high. Volume of 240.6K shares was 1.37× its 20-day average (above normal).
Split-adjusted performance: -29.2% over one month, -62.4% over six months, -44.0% over one year.
Short interest was 2.4M shares at the Oct 15 settlement, down 1.2% from the prior report (6.0% of float, 18.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| NERVMinerva Neurosciences | $2.35 | +0.21% | −62.4% | — | — | — | $112.2M | |
| EQEquillium | $1.41 | +2.17% | −31.9% | — | — | — | $110.5M | Compare |
| NKTXNkarta | $1.53 | +0.66% | −50.3% | — | — | — | $109.6M | Compare |
| ORGOOrganogenesis Holdings | $0.8350 | +10.52% | −67.8% | −56.7% | −227.0% | — | $107.4M | Compare |
| ANIXAnixa Biosciences | $3.06 | +2.17% | +1.8% | — | — | — | $106.2M | Compare |
| HURATuHURA Biosciences | $1.66 | −3.78% | −28.7% | — | — | — | $105.5M | Compare |
| IMUXImmunic | $7.60 | +3.54% | −32.6% | — | — | — | $103.7M | Compare |
| SPRBSpruce Biosciences | $42.81 | −3.91% | −27.9% | — | — | — | $123.0M | Compare |
| PDSBPDS Biotechnology | $1.41 | +2.92% | +33.0% | — | — | — | $102.2M | Compare |
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
